Rapafusyn’s Board of Directors appoint Gordon Ringold, PhD as Executive Director. Gordon Ringold, Ph.D., is CEO of Quadriga BioSciences and is currently on the board of directors of Sagimet, Apexigen, Rapafusyn and Okava Pharmaceuticals.

From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Dr. Ringold was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies to accelerate the pace of drug discovery; prior to that he was VP and Director of the Institute for Cancer and Developmental Biology at Syntex Corporation (1986-1991).